期刊文献+

胃癌中抑癌基因Kruppel样因子6 mRNA与蛋白的表达及其意义 被引量:1

Expression and significance of tumor suppressor gene Kruppel-like transcription factor 6 mRNA and protein in gastric cancer
原文传递
导出
摘要 目的 研究Kruppel样因子6(KLF6)基因表达与胃癌发生、发展的关系.方法 采用免疫组织化学(SP法)与反转录-聚合酶链反应(RT-PCR)对73例胃癌及癌旁组织的KLF6蛋白与mRNA表达进行检测,分析KLF6表达与临床病理因素间的关系.结果 KLF6蛋白在胃癌及癌旁组织中的表达率分别为39.7%(29/73)、90.4%(66/73) (P<0.01),在低、高-中分化癌组织中的表达率分别为25.0%(10/40)、57.6%(19/33)(P<0.01).KLF6mRNA在胃癌及癌旁组织中表达水平(与GAPDH吸光度比值)分别为0.1586±0.1071、0.8899±0.0638 (P<0.01).结论 KLF6蛋白与mRNA在胃癌组织中呈低表达,且在低分化胃癌中低于高-中分化胃癌,表明KLF6与胃癌的发生、发展及分化关系密切,可作为判断胃癌生物学行为的重要指标. Objective To investigate the correlation between Kruppel-like transcription factor 6 (KLF6) and gastric cancer.Methods By using immunohistochemistry (IHC) and reverse transcription PCR,the expression of KLF6 protein and mRNA in human gastric carcinoma specimens and adjacent tissues from 73 patients were examined.Results The KLF6 protein expression rates were 39.7 % (29/73) and 90.41%(66/73) in 73 cases of gastric cancer and adjacent tissues,The KLF6 protein expression was significantly lower in human gastric carcinomas than the adjacent tissues by chi-square test (P 〈 0.01).The KLF6 expression rates were 25.0 % (10/40),57.6 % (19/33) in poorly and well differentiated cancer.The difference between the two groups was significant (P 〈 0.01).The optical density ratio of KLF6 mRNA were 0.1586±0.1071 and 0.8899±0.0638 in the gastric cancer and cancer adjacent tissue respectively,the difference between the two groups was significant (P 〈 0.01).Conclusion KLF6 expression is low in gastric carcinoma,and moreover,KLF6 expression is significantly lower in poorly differentiated cancers than the well differentiated gastric cancers,there are negative correlation between KLF6 and gastric cancer,therefore KLF6 could be a useful marker for gastric cancer.
出处 《肿瘤研究与临床》 CAS 2013年第10期681-684,共4页 Cancer Research and Clinic
基金 合肥市医学重点学科建设计划
关键词 胃肿瘤 反转录聚合酶链反应 免疫组织化学 Kruppel样转录因子类 Stomach neoplasms Reverse transcriptase polymerase chain reaction Immunohistochemistry Kruppel-like transcription factors
  • 相关文献

参考文献16

  • 1Naria G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science, 2001, 294: 2563-2566.
  • 2Lang UE, Kocabayoglu P, Cheng GZ, et al. GSK3 [3 phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene, 2013, 32: 4557-4564.
  • 3尹宜发,徐弘,李思维,等.乳腺癌中环氧合酶2与p53的表达及其与预后的关系月中瘤研究与临床,2012,24:20.23.
  • 4Spinola M, Leoni VP, Galvan A, et al. Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene. Cancer Lett, 2007, 251:311-316.
  • 5Wei J, Zhao J, Long M, et al. p21WAF1/CIPI gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to eisplatin in lung carcinoma cell. BMC Cancer, 2010, 10: 632.
  • 6Sangodkar J, Shi J, DiFeo A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer, 2009, 45: 666-676.
  • 7DiFeo A, Martignetti JA, Narla G. The role of klf6 and its splice variants in cancer therapy. Drug Resist Updat, 2009, 12:1-7.
  • 8Miele L, Beale G, Patman G, et al. The Krupi l-like factor 6 genntype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology, 2008, 135: 282-291.
  • 9Siraeh E, Bureau C, Pradayrul L, ct al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ, 2007, 14: 1202-1210.
  • 10Yea S, Narla G, Zhao X, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatncellular carcinoma. Gastroenterology, 2008, 134:1521 -1531.

二级参考文献12

  • 1Saltz LB, Meropol NJ, Loehrer PJ Sr, et al Phase lI trial of cetuximab in patients with .refractory colorectal cancer that expresses the epidermal growth factor receptor. J CIin Oncol, 2004, 22: 1201-120g.
  • 2Schmoll HJ, Cartwright T, Tabemero J, et al. Phase I trial of capecitabine plus oxaliplatin as adjuvant therapy for stage 1R eoloncaneer: a planned safety analysis in t, 864 patients. J Clin Oncol, 2007, 25: 102-109.
  • 3Freeman D, Juan T, Reiner lV[, et al. Association of K-ras mutational status and clinical outcomes in patient swith metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer, 2008, 7: 184-190.
  • 4Bokemeyer C, BondarenkQ I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without eetuximab: the OPUS expe'ience. J Clin Oneol, 2008, 26." 4000.
  • 5van Cutsem E, Lang I, Dhaens G, et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol, 2008, 26: 2.
  • 6Stintzing S, I-leinemann V, Moosraann N, et al. The treatment of colorectal carcinoma with monoclonal antibodies the importance of KRAS mutation analysis and EGRF status. Dtsch Arztebl Int, 2009, 106: 202-206.
  • 7Dieterle CP, Conzelmann M, Linnemann U, et al. Detection of isolated tumor cells by polymerase chain reaction restriction fragment length polyrnorphism for K-ras mutation in tissue samples of 199 olorectal Cmacer patients. Clin Cancer Res, 2004, 10: 641-650.
  • 8hang YS, Yeh KT, Chang TJ, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer, 2009, 9: 179.
  • 9吴文辉,肖隆斌,汤友珍,蔡世荣,詹文华.K-ras基因突变与结直肠癌生物学行为的关系[J].中国病理生理杂志,2009,25(11):2159-2162. 被引量:19
  • 10陈慧娟,李洪波,李硕敏,鲁碧稳,程俊峰,刘元力.k-ras基因突变与结直肠癌的关系[J].肿瘤研究与临床,2010,22(7):461-463. 被引量:8

共引文献1

同被引文献10

  • 1Yasui W,Yokozaki H,Fujimofo J,et al.Genetic and epigenefie altera-tions in muhistep carcinogenesis of the stonmch[J].J Gastroemerol,2000,35(Suppl 12):111-115.
  • 2Vogelstein BFearon ER,Hamilton SR,et al.Genetic alterations dur-ing colorectal tumor development[J].New Eng J Med,1998,319(9):525-532.
  • 3Hamihon SR.Aaltonen LA.World Health Organization classificationof tumors:Pathology and genetics of tumors of digestive system[M].Lyon:IARC Press,2000:37-68.
  • 4Narla G,Kremer-Tal S,Matsumoto N,et al.In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liverand human hepatocellular carcinoma[J].Oncogene,2007,26(30):4428-4434.
  • 5Hsieh CL,Chen KC,Ding CY,et al.Valproic acid substantiallydownregulated genes folrl,IGF2R,RGS2,COL6A3,EDNRB,KLF6,and pax-3,N-acetylcysteine alleviated most of the inducedgene alterations in chicken embryo model[J].Rom J Morphol Embry-ol,2013,54(4):993-1004.
  • 6Date D,Das R,Narla G,et al,Kruppel-Iike Transcription Factor 6Regulates Inflammatory Macrophage Polarization[J].J Biol Chem,2014,289(15):10318-10329.
  • 7Gehran RC,Dastolfo DS,Prieto C,et al.Genomic organization andfunctional analysis of the gene encoding the Kruppel-Iike transcriptionfactor klfc[J].Biochim Biophys Acta,2005,1730(2):137-146.
  • 8Tahara E,Kadara H,Lacroix L,et al.Activation of protein kinase Cby phorbol 12-myristate 13-acetate suppresses the growth of lung canc-er cells through klf6 induction[J].Cancer Biol Ther,2009,8(9):801-807.
  • 9Yea S,Narla G,Zhao X,et al.Ras promotes growth by alternativesplicing-mediated inactivation of the klf6 tumor suppressor in hepato-cellular carcinoma[J].Gastroenterology,2008,134(5):1521-1531.
  • 10Leow CC,Wang BE,Ross J,et al.Prostate specific Klf6 inactivationimpairs anterior prostate branching morphogenesis through increasedactivation of the Shh pathway[J].J Biol Chem,2009,284(31):21057-21065.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部